Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy

Int J Mol Sci. 2022 Oct 28;23(21):13096. doi: 10.3390/ijms232113096.

Abstract

Doxorubicin, which is widely used to treat a broad spectrum of malignancies, has pronounced dose-dependent side effects leading to chronic heart failure development. Nicotinamide riboside (NR) is one of the promising candidates for leveling the cardiotoxic effect. In the present work, we performed a comparative study of the cardioprotective and therapeutic actions of various intravenous NR administration modes in chronic doxorubicin-induced cardiomyopathy in Wistar rats. The study used 60 mature male SPF Wistar rats. The animals were randomized into four groups (a control group and three experimental groups) which determined the doxorubicin (intraperitoneally) and NR (intravenous) doses as well as the specific modes of NR administration (combined, preventive). We demonstrated the protective effect of NR on the cardiovascular system both with combined and preventive intravenous drug administration, which was reflected in a fibrous tissue formation decrease, reduced fractional-shortening decrease, and better antioxidant system performance. At the same time, it is important to note that the preventive administration of NR had a more significant protective effect on the animal organism as a whole. This was confirmed by better physical activity parameters and vascular bed conditions. Thus, the data obtained during the study can be used for further investigation into chronic doxorubicin-induced cardiomyopathy prevention and treatment approaches.

Keywords: NAD+; anthracyclines; doxorubicin-induced cardiomyopathy; fibrosis; intravenous administration; nicotinamide riboside; sirtuins.

MeSH terms

  • Animals
  • Cardiomyopathies* / chemically induced
  • Cardiomyopathies* / drug therapy
  • Cardiomyopathies* / prevention & control
  • Doxorubicin / adverse effects
  • Male
  • NAD
  • Niacinamide* / pharmacology
  • Niacinamide* / therapeutic use
  • Pyridinium Compounds / pharmacology
  • Pyridinium Compounds / therapeutic use
  • Rats
  • Rats, Wistar

Substances

  • nicotinamide-beta-riboside
  • Niacinamide
  • Pyridinium Compounds
  • Doxorubicin
  • NAD